Back to top
more

Amphastar Pharmaceuticals (AMPH)

(Delayed Data from NSDQ)

$50.53 USD

50.53
262,685

-0.25 (-0.49%)

Updated Oct 31, 2024 04:00 PM ET

After-Market: $50.57 +0.04 (0.08%) 6:48 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (98 out of 251)

Industry: Medical - Generic Drugs

Better trading starts here.

Zacks News

Zacks Industry Outlook Highlights Dr. Reddy's Laboratories, Amphastar Pharmaceuticals and Sol-Gel Technologies

Dr. Reddy's Laboratories, Amphastar Pharmaceuticals and Sol-Gel Technologies are part of the Zacks Industry Outlook article.

Amphastar Pharmaceuticals (AMPH) Laps the Stock Market: Here's Why

The latest trading day saw Amphastar Pharmaceuticals (AMPH) settling at $45.19, representing a +1.23% change from its previous close.

Sundeep Ganoria  headshot

3 Generic Drug Stocks to Watch Amid Improving Market Prospects

The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide some respite to RDY, AMPH and SLGL.

Amphastar Pharmaceuticals (AMPH) Rises As Market Takes a Dip: Key Facts

In the closing of the recent trading day, Amphastar Pharmaceuticals (AMPH) stood at $44.72, denoting a +0.52% change from the preceding trading day.

Amphastar Pharmaceuticals (AMPH) Laps the Stock Market: Here's Why

Amphastar Pharmaceuticals (AMPH) closed at $46.47 in the latest trading session, marking a +1.55% move from the prior day.

Are Medical Stocks Lagging Amphastar Pharmaceuticals (AMPH) This Year?

Here is how Amphastar Pharmaceuticals (AMPH) and Acadia Pharmaceuticals (ACAD) have performed compared to their sector so far this year.

Amphastar Pharmaceuticals (AMPH) Rises Higher Than Market: Key Facts

In the closing of the recent trading day, Amphastar Pharmaceuticals (AMPH) stood at $47.55, denoting a +0.76% change from the preceding trading day.

Amphastar Pharmaceuticals (AMPH) Stock Sinks As Market Gains: What You Should Know

Amphastar Pharmaceuticals (AMPH) closed the most recent trading day at $45.74, moving -0.54% from the previous trading session.

Amphastar Pharmaceuticals (AMPH) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Amphastar Pharmaceuticals (AMPH) closed at $45.88, marking a +0.81% move from the previous day.

Amphastar Pharmaceuticals (AMPH) Dips More Than Broader Markets: What You Should Know

Amphastar Pharmaceuticals (AMPH) closed the most recent trading day at $46.04, moving -0.41% from the previous trading session.

Should You Invest in Amphastar (AMPH) Based on Bullish Wall Street Views?

Based on the average brokerage recommendation (ABR), Amphastar (AMPH) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Amphastar Pharmaceuticals (AMPH) Stock Sinks As Market Gains: What You Should Know

Amphastar Pharmaceuticals (AMPH) closed the most recent trading day at $46.30, moving -0.73% from the previous trading session.

Amphastar Pharma (AMPH) Stock Skyrockets 89% YTD: Here's Why

Amphastar Pharma (AMPH) shares are up 89.1% year to date due to the acquisition of Baqsimi from Lilly. The company also receives FDA approval for Naloxone.

Eli Lilly (LLY) Stock Up Almost 50% Year to Date: Here's Why

Sales of Lilly's (LLY) new drug, Mounjaro are already benefiting from strong demand trends. Lilly expects regulatory decisions for some key pipeline candidates this year, which are key to growth.

HCA Healthcare (HCA) Rises 24% in a Year: More Room to Run?

HCA Healthcare (HCA) is well-poised for growth on the back of improved patient occupancy levels, effective telehealth services suite and solid cash-generating abilities.

Santanu Roy  headshot

Take the Zacks Approach to Beat the Markets: Celsius, Adobe, Curtiss-Wright in Focus

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Dr. Reddy's Laboratories and Teva Pharmaceutical

Amphastar Pharmaceuticals, Dr. Reddy's Laboratories and Teva Pharmaceutical are part of the Zacks Industry Outlook article.

Is Amphastar (AMPH) a Solid Growth Stock? 3 Reasons to Think "Yes"

Amphastar (AMPH) could produce exceptional returns because of its solid growth attributes.

Cigna (CI) Unit Ties Up to Offer Digital Health Tool to Clients

Cigna's (CI) division, Cigna Healthcare, teams up with Virgin Pulse to make an effective digital health solution available to its clients, who can now improve their well-being.

Sundeep Ganoria  headshot

3 Generic Drug Stocks to Watch Amid Improving Market Prospects

The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide some respite to AMPH, RDY and TEVA.

Is Amphastar Pharmaceuticals (AMPH) Stock Outpacing Its Medical Peers This Year?

Here is how Amphastar Pharmaceuticals (AMPH) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.

Dr. Reddy's Laboratories Ltd (RDY) Hits Fresh High: Is There Still Room to Run?

Doctor Reddy's (RDY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Beat Estimates

Amphastar (AMPH) delivered earnings and revenue surprises of 14.04% and 6.20%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

TEVA Q2 Earnings & Sales Top as Austedo Outperforms, Stock Up

TEVA's second-quarter results were strong as it beat estimates for earnings as well sales.

BridgeBio Pharma (BBIO) Reports Q2 Loss, Misses Revenue Estimates

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -13.95% and 65.14%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?